We have previously demonstrated that protein kinase B (PKB) is a mediator of heat-induced apoptosis for human breast cancer cells. To investigate the therapeutic potential of abrogating the function of this important survival protein, a novel replication-deficient adenovirus was constructed, wherein a mutant, kinase-inactive PKB gene (AAA) was inserted downstream of the CMV promoter. Two human breast cancer cell lines, MCF-7 and MDA-468, were treated, along with the MCF-10 serving as a ''normal'' mammary epithelial comparator. Apoptosis was increased with adv.AAA (25 PFU/cell) infection alone, but was significantly enhanced with the addition of heat exposure. Differential survival was observed with the MDA-468 cancer cells being more sensitive than the MCF-7 cells. The MCF-10 cells, in contrast, were most resistant to these treatments. Results from the clonogenic assay reflected the apoptosis data, with an apparent additive interaction between adv.AAA and hyperthermia treatments, again with greater differential sensitivity of the malignant, compared to the ''normal'' mammary epithelial cells. Heat or adv.b-gal treatments led to phosphorylation of PKB and Forkhead, but this phosphorylation was reduced with adv.AAA therapy. In parallel, the combination of adv.AAA and heat treatment reduced PKB kinase activity more so than with either heat or adv.b-gal alone. In conclusion, our results demonstrate that inhibition of the PKB-dependent survival pathway will promote apoptosis and thermosensitization in malignant breast cancer cells, with relative sparing of their normal counterpart, suggesting that a therapeutic gain could be achievable using this therapeutic strategy.
H yperthermia (HT) is an experimental cancer treatment modality, which, in combination with ionizing radiation therapy (RT), achieves superior local control over that observed with RT alone for several tumor sites. [1] [2] [3] [4] [5] This has been demonstrated in multiple Phase III randomized studies, including a breast cancer trial, whereby 60% local control rate (LCR) was achieved when recurrent chestwall breast cancer was treated with RT plus HT vs. 39% LCR with RT alone. 5 These highly promising data have continued to motivate us to develop improved biological therapies, which can further improve these clinical data.
The detailed mechanisms of heat-induced cytotoxicity or apoptosis remain to be clearly elucidated, 6 but several signaling proteins are important mediators of this response, including heat-shock proteins and protein kinase B (PKB, also termed Akt). PKB has been consistently demonstrated to be a critical survival protein for many systems (reviewed in Nicholson and Anderson 7 ; Lawler and Alessi 8 ), by brokering a myriad of downstream prosurvival or antiapoptotic signals. Targets of PKB include transcription factors such as Forkhead 9 or NF-kB, 10 apoptotic proteins such as Bad, 11, 12 and cell cycle inhibitors such as p27. 13 We and others have shown that heat leads to the phosphorylation and activation of PKB, via the PI(3)K pathway. [14] [15] [16] Through this process, PKB also mediates heat sensitivity in the human breast cancer MCF-7 cells. 14 MCF-7 stable transfectants expressing a kinase-dead mutant of PKB (AAA) demonstrated a marked propensity to undergo heat-induced apoptosis, associated with reduced clonogenicity. Following upon this observation, we were interested in evaluating whether thermosensitization can be achieved by inhibiting this pathway using a therapeutic strategy.
We chose a gene transfer strategy utilizing the adenoviral (adv) vector, because of high infection efficiency of human epithelial cells by adenoviruses, and our extensive experience with this form of cancer gene therapy. 17 , 18 Our results demonstrate that inhibiting the PKB pathway using this specific tactic achieves thermosensitization of malignant breast cancer cells, with relative sparing of the normal mammary epithelial cells. However, adv infection itself will also upregulate PKB kinase activity in these cells, suggesting that alternative vehicles to interfere with this pathway might attain even greater efficacy.
Materials and methods

Cell cultures
Human breast cancer MCF-7 and MDA-MB-468 cell lines were grown in a-MEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. Normal mammary epithelial MCF-10A cells were maintained in growth medium containing 1:1 (v/v) mixture of Ham's F12 medium and DMEM supplemented with 2 mM L-glutamine and 5% horse serum (HS), 20 ng/ml of epidermal growth factor, 100 ng/ ml of cholera toxin, 0.01 mg/ml of insulin, and 500 ng/ml of hydrocortisone. All three breast cell lines were originally purchased from ATCC (Manassas, VA). The fetal renal 293 cells used for viral propagation were also maintained in a-MEM supplemented with 10% FBS.
Reagents and antibodies
Human epidermal growth factor, horse serum, and cholera toxin were purchased from GIBCO (Burlington, Canada). Phospho-Ser473 antibody, phospho-HR, and the Akt/PKB Kinase Assay Kit were obtained from New England Biolabs (Beverly, MA). The secondary antirabbit antibody was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Hydrocortisone, wortmannin, and all other chemicals were obtained from Sigma (St Louis, MO). Protein Analysis Reagent was purchased from Bio-Rad Laboratories (Hercules, CA).
Construction of Adv.CMV. AAA vector
The coding sequence of the dominant-negative mutant PKB (AAA) gene was subcloned from pcDNA3.HA-PKB.AAA (Xho) (from JW) as an EcoRI/XhoI fragment into the adenoviral shuttle vector pDE1Sp1B.CMV (following an EcoRI/XhoI partial digest). The pDE1Sp1B.CMV plasmid had been created previously by replacing the multiple cloning site of pDE1Sp1 (Microbix) with a SalI/BamHI fragment derived from pRc/CMV (Invitrogen) containing its CMV promoter, multiple cloning sites, and the bovine growth hormone polyadenylation signal.
The resulting plasmid pDE1Sp1B.CMV.PKB.AAA was then used to create a recombinant replicationdefective (DE1/E3) adenovirus adv.CMV.PKB.AAA (denoted herein as adv.AAA) (schema shown in Fig 1) . The resulting virus was generated by homologous recombination using calcium phosphate cotransfection with pDE1Sp1B.CMV.PKB.AAA and the E1-deleted adenoviral genomic plasmid pJM17 (Microbix, Toronto, Canada) in 293 cells. Purified viral plaques were screened by PCR and Western blotting. Propagation and titer estimation of the recombinant adenovirus was performed using standard methods, as previously described. 19 
Detection of Adv.CMV. b-galactosidase expression
The control reporter vector was adv.b-galactosidase (adv.b-gal), generated as previously described. 20 b-Galactosidase activity in MCF-7, MDA-MB-468, and MCF-10A cells was detected by counting the proportion of ''blue'' cells after X-galactosidase staining in infected cells. 20 Cells were seeded onto six-well culture plates at a density of 2 Â 10 5 cells per well, and incubated at 371C under 5% CO 2 for 24 hours. The cells were then infected at multiplicities of infection (MOIs) of 1-50 PFU/cell for 1 hour with 1 ml of a-MEM containing 2% heatinactivated FBS (561C Â 60 0 ). An hour after infection, 2 ml of a-MEM containing 10% FBS or 2 ml of 5% HS growth medium were added, and incubated for another 24 hours. After removing the medium, cells were washed three times with cold PBS, and fixed with 0.02% formaldehyde and 0.2% glutaraldehyde for 5 minutes on ice. The cells were washed with 0.02% NP-40 PBS containing 2 mM MgCl 2 for 5 minutes, and stained with X-galactosidase and immediately counted under the light microscope as described previously. 14, 20 Western blotting analysis
The expression of phosphorylated PKB or phosphoForkhead was determined with immunoblot analysis after adv.AAA, adv.b-gal infection, or heat treatment. Cells were seeded at a density of 5 Â 10 5 cells onto 25 cm 2 Tflasks (Nunc, Roskilde, Denmark) and allowed to grow for 24 hours. Cells were then infected with 25 PFU/cell of adv.AAA or adv.b-gal for 1 hour and maintained in 5 ml 10% FBS -MEM for another 24 hours, then the cells were starved overnight using a-MEM with 1% FBS. After treatment with either control (371C) or heating (431C) for 30 minutes, the cells were scraped onto 300 ml of lysis buffer containing 0.1 mM phenylmethylsulphonyl fluoride (PMSF), 100 mM NaF 2 , 1 mM benzamidine, 10 mM NaCl, 20 mM HEPES (pH 7.0), 0.5% NP40, 0.05% Figure 1 A schema of the DE1/E3 adenoviral vector, mediating the kinase-dead PKB mutant (AAA). Its expression is driven by the CMV promoter, followed by the bovine growth hormone polyadenylation signal.
Kinase-dead PKB gene therapy N Ma et al 2-b-mercaptoethanol, and 5 mM EDTA. The lysate was then collected and kept on ice for 10 minutes, after which it was centrifuged at 13,000 rpm for 10 minutes at 41C. The supernatant was then transferred into fresh tubes, and protein concentration was determined by the Protein Analysis Reagent. Equal amounts of protein (20 mg) was subjected to 10% SDS/PAGE. After electrophoresis, the protein was transferred onto nitrocellulose membrane (Schleicher & Schuell, Keene NH). Blots were probed using the respective primary antibodies (phospho-ser473-PKB (1:1000), phospho-FKHR (1:1000), or actin) in TBST buffer containing 2 mM Tris.HCl, 0.8% NaCl, 0.1% Tween-20 pH 7.6 with 5% BSA overnight at 41C. After washing with TBST buffer, the blots were incubated with the secondary antibody (anti-rabbit IgG conjugated-HRP) at room temperature for 2 hours. Following washing, the target protein was detected using chemiluminescence (ECL Kit, DuPont, MA).
PKB kinase assay
The cells were treated as described above in the Western blotting, and harvested into cell lysis buffer. The PKB kinase assay was conducted as outlined in the protocol (New England Biolabs), and previously described.
14 In brief, 20 ml of immobilized Akt 1G1 monoclonal antibody was washed twice in the microcentrifuge tube using lysis buffer. A volume of 200 ml of cell lysate containing 150 mg of protein was added and incubated at 41C with gentle rocking for 2 hours. The immunocomplex was precipitated by centrifugation and washed twice with 500 ml of lysis buffer, and once with 500 ml of kinase buffer on ice. The kinase reaction was initiated by suspending the immunocomplex in 40 ml of kinase buffer supplemented with 200 mM ATP and 1 mg of GSK-3 fusion protein at 301C for 30 minutes. The reaction was terminated with the addition of 20 ml of 3 Â sample buffer. The sample tube was vortexed, then the supernatant was transferred into a new tube, boiled for 5 minutes, and 20 ml of the sample was subjected to 15% SDS-PAGE. Following electrophoresis, protein was transferred onto a nitrocellulose membrane as in immunoblotting. The membrane was then incubated with TBST buffer containing phospho-GSK-3 a/b (Ser21/9) antibody (at 1:1000). After washing, the membrane was incubated with HRP-conjugated antirabbit secondary antibody (1:2000) , and HRP-conjugated anti-biotin antibody (1:1000) at room temperature for 1 hour. After washing, the blot was again visualized using the ECL kit.
Apoptosis assay
Details of the apoptosis assay have been described previously, 14, 20 but in brief, MCF-7, MDA-468, or MCF-10A cells were grown and infected as described above. After 24 hours of infection, cells were control treated (371C), or heated at 431C for 60 minutes, then incubated at 371C with 5% CO 2 for 48 hours. The cells were then washed with cold PBS and trypsinized. The medium, PBS, and trypsinized cells were collected and pelleted at 2500 rpm for 5 minutes at 41C. The pellet was then resuspended in 2 ml cold PBS and respun under the same condition. The pellets were resuspended in 0.5 ml PBS and mixed with 15 ml of acridine orange and 15 ml of ethidium bromide (100 mg/ml in PBS, respectively). The stained cells were kept on ice for 30 minutes, after which they were again pelleted and resuspended in 30 ml of 10% glycerol in PBS. A 15 ml of the cell suspension was plated onto glass slides and protected with cover slides. The stained cells were analyzed immediately under fluorescent microscopy. The proportion of cells demonstrating morphologic features of apoptosis 21 was then counted. For each sample, at least 1000 cells were evaluated, and the apoptosis ratio was subsequently calculated.
Clonogenic assay
Details of the clonogenic assay have also been provided previously, 20, 22 but in brief, MCF-7, MDA-468, or MCF-10A cells were seeded in 25 cm 2 T-flask (Falcon, Franklin Lakes, NJ) and infected as described above. The cells were infected with 25 PFU/cell adv.AAA or adv.b-gal for 1 hour, and 5 ml of a-MEM containing 10% FBS or 5 ml of 5% HS growth medium was added and further incubated for an additional 24 hours. After heating at 431C for the stipulated duration (0-120 minutes), cells were trypsinized, counted, and seeded onto 100 mm 2 dishes (Nunc) in the range of 1 Â 10 2 -8 Â 10 3 cells/dish. After incubating at 371C under 5% CO 2 for 14 days, the number of colonies (at least 50 cells) from triplicate dishes was scored, and normalized for the plating efficiency from that experiment.
Statistical analysis
The apoptosis data were analyzed using the Students' ttest, as performed with the Origin 50 software (Microcall Software Inc., Norcross, GA).
Results
Infection efficiency and expression of breast cell lines
To ensure that our biochemical and cellular end points would be comparable between the three breast cell lines used for these studies, we determined the adenoviral infection efficiency of the MCF-7, MDA-MB-468, and MCF-10A cells. As demonstrated in Figure 2a , 24 hours after infection with adv.b-gal, we observed the expected dose-response relationship for the proportion of X-gal staining cells. Viral transduction efficiency was slightly reduced for MCF-7 cells compared to either MDA-MB-468 or MCF-10A cells. However, at a viral dose of 425 PFU/cell, more than 85% of all three cell lines were expressing the b-galactosidase gene.
Infection of MCF-7 cells with adv.AAA resulted in significant expression of the desired protein. This was demonstrated by conducting a Western blot against HA, since the AAA plasmid was tagged with HA. The resulting immunoblot demonstrates intense expression of HA in the MCF-7 cells infected with adv.AAA (10 PFU/cell), in contrast to undetectable HA protein in the uninfected MCF-7 cells (Fig 2b) .
Phospho-PKB and P-FKHR expression after treatment
In order to interpret the effect of adv.AAA. on P-PKB expression of infected cells, we evaluated phospho-PKB expression after infection with adv.b-gal alone. Using an antibody specific for phosphorylation of ser473 on PKB (New England Biolabs), we observed that adv.b-gal infection alone induced phosphorylation of PKB in a dose-dependent manner, from 1-25 PFU/cell, in the treated MCF-7 cells (Fig 3a) . However, adv.AAA infection alone also induced phosphorylation of PKB (lanes 3-7), although its extent of induction was slightly less compared to that of adv.b-gal alone (lanes 8-12) .
This differential in P-PKB induction between adv.AAA and adv.b-gal infection is enhanced when the cells are also treated with HT (431C Â 30 0 ). This is demonstrated in Figure 3b , whereby heat alone induced phosphorylation of PKB (lane 6). At comparable doses of adv.AAA or adv.b-gal, (5 or 25 PFU/cell), it is evident that P-PKB induction is reduced when the MCF-7 cells are treated with HT plus adv.AAA (lanes 7 and 8) vs. HT plus adv.bgal (lanes 9 and 10).
FKHRL1 is a member of the Forkhead family of transcription factors and is one of the downstream targets of PKB activation, 9 by phosphorylation at Thr32. Using a specific antibody probing for phosphorylation of FKHRL1 at this site, it is apparent that phospho-FKHRL1 expression follows a similar pattern to that observed for P-PKB, suggesting that the two signaling proteins are likely acting in a concerted manner (Fig 3b) .
The only exception appears to be the cotreatments of HT plus adv.b-gal at 25 PFU/cell, where phospho-FKHRL1 expression is reduced to a similar level to that observed for control cells (lanes 1 vs. 10).
PKB kinase activity after treatment
While phosphospecific antibodies are useful tools to monitor the phosphorylation status of PKB activation sites, it is also important to directly monitor PKB kinase activity (Fig 4) . Using GSK-3 as the substrate, it was evident that adv.b-gal alone (5 or 25 PFU/cell) induced PKB kinase activity in a dose-dependent manner (lanes 4 and 5). Similarly, heat alone (431C for 30 mintues) also induced PKB kinase activity (lane 6). However, PKB kinase activity was reduced when MCF-7 cells were treated with HT plus adv.AAA (lanes 7 and 8), than HT with adv.b-gal (lanes 9 and 10), indicating compromised 3-7) or adv.b-gal (lanes 8-12) using doses ranging from 1 to 25 PFU/cell, cells were harvested and immunoblot analysis were performed using an anti-phospho-PKB (Ser473) antibody. Actin was probed to ensure equal protein loading in each lane. For negative and positive controls, MCF-7 cells were either untreated or exposed to EGF (10 ng/ml for 15 minutes) (lanes 1 and 2, respectively). (b) MCF-7 cells were treated with either heat alone (431C for 30 minutes), or heated 24 hours after infection with either adv.b-gal or adv.AAA (5 or 25 PFU/cell). Immunoblotting was subsequently conducted 24 hours after heating using anti-phospho-PKB (Ser473), phospho FKHRL1 (Thr32), or actin antibodies.
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Adv.AAA enhances heat-induced apoptosis
Apoptosis was evaluated using AO-EB staining after cells were treated with adv.b-gal, adv.AAA, or combined with HT (431C Â 60 minutes). For both MCF-7 and MDA-MB-468 cells, adv.b-gal infection induced minimal apoptosis, in contrast to adv.AAA alone (panels a vs. b in Fig 5a and b) . Heat plus adv.b-gal also induced apoptosis (panel d in Fig 5a and b) , but the greatest proportion of apoptotic cells was observed with the combination of adv.AAA plus HT (Panel c's in Fig 5) .
These data are summarized quantitatively in Figure 6 . Adv.AAA infection alone increased the proportion of apoptotic cells in all three breast cell lines, particularly for the two cancer cell lines (MCF-7 and MDA-MB-468). In these two malignant lines, the proportion increased by 3-4-fold, whereas in the ''normal'' mammary epithelial MCF-10A cells, this proportion increased minimally from 3 to 5%. This differential between the malignant cells and the MCF-10A cells was statistically significant (Po.05). Heat alone caused apoptosis in 5, 18, and 7% respectively, among the MCF-7, MDA-MB-468, and MCF-10A cells.
The induction in apoptosis was further enhanced when HT was added (431C Â 60 minutes). The percentage of apoptotic MCF-7, MDA-MB-468, and MCF-10A cells were 21, 30, and 17% respectively, with the combination of adv.AAA (25 pfu/cell) plus HT. These differences were all statistically significant from each other at P-values o.05, with the greatest sensitivity observed for the MDA-MB-468 cells. The most resistant cell line of the three was the ''normal'' mammary epithelial MCF-10A line. This combination regimen recapitulates the previous observation with adv.AAA infection alone, of the relative sparing of normal cells.
Cytotoxic effects of Adv.AAA infection combined with HT
The pattern of clonogenic survival mostly reflects that of the apoptotic data for all three breast cancer cell lines. With increasing duration of heating at 431C (0-120 minutes), all cell lines demonstrated a time-dependent reduction in clonogenic survival, although the extent of reduction was least for the MCF-10A cells (Fig 7c) .
Adv.b-gal plus heat achieved maximally 20% cytotoxicity for these cells. Adv.AAA (25 PFU/cell) alone also caused cytotoxicity in all three lines, but in contrast to the apoptosis data, the MDA-MB-468 cells appeared to be Figure 4 MCF-7 cells were treated as described in Figure 3 , and then PKB was isolated with an immobilized Akt 1G1 monoclonal antibody. The kinase assay was performed using GSK-3 fusion protein as a substrate. Figure 5 MCF-7 (a) and MDA-468 (b) cells were infected with either adv.AAA or adv.b-gal (25 PFU/cell). After 24 hours, cells were heated at 431C for 60 minutes, and then incubated at 371C under 5% CO 2 for 48 hours. Thereafter, the cells were stained with acridine orange and ethidium bromide, and the proportion of apoptotic cells was counted immediately under fluorescent microscopy. At least 1000 cells were counted and scored for each sample.
Kinase-dead PKB gene therapy N Ma et al least sensitive to this treatment, in contrast to the other two lines. When the two treatments of HT plus adv.AAA were combined, the two modalities appear to be interacting in an additive manner, but retaining differential sensitivity between the three lines. MCF-7 cells appeared to be most sensitive to this combination treatment (3% survival level with adv.AAA plus 2 hours HT at 431C), and the most resistant being the ''normal'' MCF-10A cells with a 10-fold higher survival level at 32%.
Discussion
We have successfully constructed a novel adenovirus, mediating a kinase and activation-defective version of the survival protein PKB (adv. AAA). In combination with HT, we demonstrate that this combinatorial strategy causes significant cytotoxicity in vitro in two distinct human breast cancer cell lines. In addition, therapeutic gain was achieved, since the nonmalignant mammary epithelial cells were relatively resistant to this combined treatment. We also demonstrate that one important mode of cytotoxicity mediated by both adv.AAA and HT is the induction of apoptosis. Since its first discovery more than a decade ago, [23] [24] [25] PKB has been shown to be a critical protein mediating important cellular functions including survival, cell growth, and movement (reviewed in Scheid and Woodgett 26 ). It plays important roles in both physiologic and pathologic states, including diabetes, autoimmunity, and cancer. PKB can be activated by membrane signals that result in phosphorylation of phosphotidylinositol-4,5-bispohsphate (PIP 2 ) to PIP 3 , which then recruits PKB to the membrane via its pleckstrin homology domain. This membrane localization of PKB facilitates its phosphorylation at two sites: Thr308 and Ser473 (PKBa), which then signals a series of downstream events, depending on the cellular context and initial stimuli. PTEN (phosphatase and tensin homologue deleted on chromosome 10) inhibits PKB activation by virtue of its dephosphorylating role in reverting PIP 3 to PIP 2 . We and others have documented that PTEN is underexpressed in approximately 30% of human breast cancers, 27, 28 resulting in upregulation of PKB activity, which in turn is associated with reduced patient survival. 29 Hyperthermia has been demonstrated in Phase III randomized trials to benefit patients with both improved local control 1,4,5 and survival. 2 However, attainment of uniform temperature within the target tumor tissues is difficult to achieve, 30 hence any additional therapeutic manoeuvre that could enhance heat-induced cytotoxicity would be desirable. We have previously demonstrated that PKB can modulate heat sensitivity.
14 Specifically, MCF-7 cells stably expressing constitutively activated PKB (MCF-7/DD) were resistant to heat-induced apoptosis, in contrast to MCF-7 cells expressing the kinasedead version of PKB (MCF-7/AAA). In addition, the PTEN-PKB pathway is relevant in human breast cancer in that dysregulation of this pathway, as indicated by immunohistochemistry studies of patients' surgical samples, was associated with negative ER/PR status. 27 Hence, a logical extension of our research was to evaluate the potential efficacy of combining HT with a method to neutralize the PKB survival pathway.
A number of downstream targets of activated PKB, including IKK, Bad, and FKHR, are all involved in inhibiting apoptosis (see review by Nicholson and Anderson 7 ). Relevant to this study, Forkhead (FKHR) is a family of transcription factors for proapoptotic genes such as FasL or Bim. Phosphorylation of FKHR by activated PKB results in its cytoplasmic sequestration, thereby inhibiting its transcriptional activity. PKB can also affect cell cycling by inhibiting p27, p21, and cyclin D via GSK3; likewise, PKB can promote protein synthesis through phosphorylation of mTOR.
The relevance of PKB to human malignancy is firstly based on the observation of overexpression (of phospho-PKB) in human clinical tumor samples, strengthened by its prognostic value. 29 Secondly, transgenic mice expressing constitutively activated PKB contribute to the development of breast and brain malignancies. 31, 32 Hence, PKB is a logical candidate to pursue for therapeutic purposes for human breast cancer. In our study, we chose to target PKB by exogenously introducing a kinase-dead version, whereby Lys179, Thr308, and Ser473 have all been substituted by alanine, rendering it unphosphorylatable and unbindable by ATP (Lys residue). Owing to our extensive experience in cancer gene therapy utilizing the adenoviral vector, and the high transfectability of human breast cells by the adenovirus, we chose to deliver PKB-AAA using this approach.
The unexpected observation was that adenoviral infection alone (mediating the b-galactosidase reporter gene) can activate PKB in a dose-dependent manner in our system (Fig 3) . Adenoviruses enter cells via the Coxsackie adenovirus receptor (CAR) 33 with subsequent integration via a v B 3 or a v B 5 integrin receptors. 34 We suspect that it is this latter interaction which results in phosphorylation of PKB. This has been reported by other groups utilizing the adenovirus as a vehicle for PTEN in prostate cancer 35 or PKB in cardiomyocytes. 36 Close inspection of their Western blots corroborates the increase in P-PKB expression with adenoviral infections mediating reporter genes such as GFP. One possible mediator of this process is integrin-linked kinase (ILK), a widely expressed focal adhesion protein kinase, 37 which can be activated by extracellular stimuli interacting with integrin receptors (such as adenoviral entry). ILK can activate PKB, 38 hence this is one plausible mechanism for the observed P-PKB with adenoviral infection alone (Fig  3) . However, despite the increase in P-PKB expression induced by the vector, introduction of AAA results in reduction of P-PKB expression, associated with apoptosis and lower survival. Hence, the net effect is increased cytotoxicity of breast cancer cells by adv.AAA treatment.
We observe a differential sensitivity to apoptosis by adv.AAA between the two breast cancer cell lines, MDA-MB-468 and MCF-7. The former is slightly more sensitive to adv.AAA-induced apoptosis compared to the latter. One possible explanation might be related to the endogenous PTEN-PKB pathway whereby we have previously documented that the more sensitive MDA-MB-468 cells lack PTEN and have increased P-PKB expression. 27 In contrast, the MCF-7 cells have preserved PTEN expression, and undetectable phospho-PKB (in the unstimulated state). Hence, potentially, the MDA-MB-468 cells may be dependent upon activated PKB for their continued proliferation and survival. Therefore, the exogenous introduction of pharmacologic doses of kinase-dead PKB could interfere with prosurvival cascades, rendering the cells more susceptible to apoptosis. This conjecture is supported by our previous experience with introduction of wild-type p53 using adenoviral vectors (adv.wtp53), whereby cancer cells with mutant or absent p53 are far more sensitive to this therapeutic strategy than tumors with retained p53 function. 20 Another possibility, of course, could relate to the fact that MCF-7 cells lack functional caspase-3, 39 resulting in greater intrinsic resistance to apoptosis, regardless of the insult.
Another observation underscores the complexity of adv.AAA-induced cytotoxicity. Despite the increased sensitivity of MDA-MB-468 cells to apoptosis, it is in fact more resistant to adv.AAA infection in terms of clonogenic survival (Fig 7) . Infection with adv.AAA alone resulted in 20% cytotoxicity in MDA-MB-468 compared to 65% cytotoxicity for the MCF-7 cells. We have only examined apoptosis as one mode of cell death; PKB-AAA can affect a myriad of other processes, including cell cycle arrest, and inhibition of protein synthesis, all of which can contribute to reduced clonogenicity.
The mechanism of heat-induced cytotoxicity or apoptosis remains to be elucidated. Some authors contend that hyperthermia induces apoptosis in a p53-dependent manner. 40 We have previously demonstrated that the combination of adv.wtp53 and HT results in additive cytotoxicity in a human nasopharyngeal cancer cell line, which did not appear to be a synergistic interaction. 41 Gene-expression profiling has demonstrated that heat can induce caspase genes, implicating its role in apoptosis. 42 Kinase-dead PKB gene therapy N Ma et al
Our current study clearly documents that heat contributes to apoptosis in breast epithelial cells (Figs 5 and 6 ).
Immunoblotting data indicate that heat also induces phosphorylation of FKHR and PKB, along with an increase in PKB kinase activity. Such responses presumably reflect the efforts by the cell to protect itself against heat toxicity. This might be achieved through the complexing of heat-shock proteins (e.g. hsp27 or 90) with PKB, 16, 43 thereby shielding PKB against proteasomaltargeted degradation. 44 An encouraging observation from our study on the potential efficacy of targeting PKB as a cancer treatment strategy relates to the differential sensitivity between malignant and normal cells. The MCF-10 is a nonmalignant mammary epithelial cell line, and these cells demonstrate resistance to adv.AAA-induced apoptosis (Fig 6) and cytotoxicity (Fig 7) . After 2 hours of heating at 431C in combination with adv.AAA (25 PFU/cell), MCF-10 cells demonstrate a 30% survival level, in contrast to 2-3% for the malignant cells. This suggests that ''normal'' cells are less susceptible to manipulations of the PKB pathway, in contrast to the vulnerability of malignant cells. The precise reason is again not entirely clear but one can speculate that ''normal'' cells have a greater ability to maintain its homeostatic balance and respond to stress signals than their malignant counterparts. This observation has been recapitulated by others, and specifically, in our own studies whereby the ''normal nasopharyngeal fibroblasts'' were resistant to adv.wtp53 gene transfer in combination with ionizing radiation, 19 in contrast to two malignant nasopharyngeal cell lines.
In summary, the pursuit to neutralize the PKB pathway for human cancer therapy is a potentially fruitful strategy. This field is currently under intense investigation, and several agents are in preclinical or Phase I studies. 45 Based on our data using two distinct human breast cancer cell lines, it would appear that this strategy might be applicable regardless of endogenous PKB expression. Our genetic approach of introducing kinase-dead PKB is a reasonable approach, but we would recommend that for future studies, utilizing alternate vehicles, rather than the adenovirus, might achieve even greater therapeutic efficacy.
